←Back to Expert Scholars
Translational Medicine / 转化医学Cancer Trials, Biomarker Trial Design
Boris Freidlin
PhD
🏢National Cancer Institute🌐USA
Mathematical Statistician
55
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Boris Freidlin has contributed methodological work on biomarker-based trial designs including marker strategy trials and sequential enrichment approaches. His work at the NCI has shaped federal guidance on biomarker trial methodology. He has co-authored influential reviews on predictive biomarker validation.
Share:
🧪Research Fields 研究领域
biomarker trial design
adaptive design
biostatistics
oncology methodology
marker-based strategies
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Boris Freidlin 的研究动态
Follow Boris Freidlin's research updates
留下邮箱，当我们发布与 Boris Freidlin（National Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment